Skip to Main Content

Paper Details

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
Cell Rep
249
2022
B, B cell, B.1, B.1.1, B.1.1.7, B.1.351, COVID-19, LY, LY-CoV1404, LY-CoV1404 epitope, SARS, SARS-CoV, SARS-CoV-2, SARS-CoV-2 spike glycoprotein receptor, Severe acute respiratory syndrome, bebtelovimab, coronavirus disease, epitope, monoclonal antibodies
Author NameAffiliation
Lingshu WangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
J Michael Sauder
J Michael Sauder
Payal SipahimalaniAbCellera Biologics Inc.
Tongqing ZhouVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • 1 - 7

Datasets

Release 1.2